Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    APL-102

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Apollomics Doses First Patient in a Phase I Clinical Trial of APL-102
    Apollomics Doses First Patient in a Phase I Clinical Trial of APL-102

    10 Aug 2021

    // PRESS RELEASE

    https://drugdevelopment.labcorp.com/services/clinical-development.html?cid=_PSClk_CDCS_Reimagine-GoogleCT_0621_3307&gclid=EAIaIQobChMIyI2uhvyo8gIVI4ZLBR3p6AMEEAAYASAAEgJLavD_BwE&gclsrc=aw.ds

    PRESS RELEASE
    10 Aug 2021
    Share Share
    Apollomics Doses First Patient in a Phase I Clinical Trial of APL-102
    Apollomics Doses First Patient in a Phase I Clinical Trial of APL-102

    10 Aug 2021

    // PRESS RELEASE

    https://drugdevelopment.labcorp.com/services/clinical-development.html?cid=_PSClk_CDCS_Reimagine-GoogleCT_0621_3307&gclid=EAIaIQobChMIyI2uhvyo8gIVI4ZLBR3p6AMEEAAYASAAEgJLavD_BwE&gclsrc=aw.ds

    PRESS RELEASE
    10 Aug 2021
    Share Share